Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TCF7L2 |
| Gene Name: | TCF7L2 |
| Protein Full Name: | Transcription factor 7-like 2 |
| Alias: | HMG box transcription factor 4; T-cell-specific transcription factor 4; TCF4; TCF-4; TF7L2; Transcription factor 7-like 2 (T-cell specific, HMG-box) |
| Mass (Da): | 67919 |
| Number AA: | 619 |
| UniProt ID: | Q9NQB0; B9X074 |
| Locus ID: | 6934 |
| COSMIC ID: | TCF7L2 |
| Gene location on chromosome: | 10q25.3 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | MIXED |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 20146 |
| Percent of cancer specimens with mutations: | 1.01 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | TCF7L2 is a transcription factor that plays a role as a modulator of Myc expression in the Wnt signalling pathway. It can act as a repressor or an activator, depending on the presence of CTNNB1. Dominant-negative mutants result in cell-cycle arrest in G1. Constitutive activation leads to the maintenance of stem-cell characteristics in cells fated for terminal differentiation and leads to the transformation of colorectal cancer cells. |